dc.contributor
Institut Català de la Salut
dc.contributor
[Zanga G] Department of Neurology, César Milstein Hospital, associated with University of Buenos Aires, Buenos Aires, Argentina. [Drzewiscki E, Esnaola Rojas MM] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Tagliani P] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Smietniansky M] Department of Internal Medicine Interna, Programa de Medicine Geriatric Program, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. [Caruso D] Department of Internal Medicine, César Milstein Hospital, associated with University of Buenos Aires, Buenos Aires, Argentina
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Zanga, Gisela Mariel
dc.contributor.author
Drzewiscki, Estefania
dc.contributor.author
Tagliani, Paula
dc.contributor.author
Smietniansky, Maximiliano
dc.contributor.author
Esnaola Rojas, Maria M.
dc.contributor.author
Caruso, Diego
dc.date.accessioned
2025-10-24T10:31:07Z
dc.date.available
2025-10-24T10:31:07Z
dc.date.issued
2022-06-20T08:08:43Z
dc.date.issued
2022-06-20T08:08:43Z
dc.date.issued
2021-10-05
dc.identifier
Zanga G, Drzewiscki E, Tagliani P, Smietniansky M, Esnaola Rojas MM, et al. Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis. Ther Adv Neurol Disord. 2021 Oct 5;14:1–11.
dc.identifier
https://hdl.handle.net/11351/7714
dc.identifier
10.1177/17562864211031099
dc.identifier
000706298300001
dc.identifier.uri
http://hdl.handle.net/11351/7714
dc.description.abstract
Disease-modifying therapies; Multiple sclerosis; Predictors
dc.description.abstract
Terapias modificadoras de la enfermedad; Esclerosis múltiple; Predictores
dc.description.abstract
Teràpies modificadores de la malaltia; Esclerosi múltiple; Predictors
dc.description.abstract
Background and Aims:
In multiple sclerosis (MS), non-adherence/non-persistence is related to suboptimal response to treatment, including disease relapses and the need for more expensive healthcare. The aim of this study was to identify predictors related to adherence to disease modifying therapies (DMTs) in a cohort of Argentinian MS patients.
Methods:
We conducted a cross-sectional study at the National Medical Care Program from Argentina. MS patients with at least one claim for a DMT from 1 January 2017 to 1 October 2017 were identified. A telephone survey was performed to assess clinical and demographic factors. The medication possession ratio (MPR) was used to estimate adherence; MPR <80% defined non-adherence. Associations were studied using a logistic regression model.
Results:
Our database included 648 MS patients. A total of 360 patients (60% females, mean age 55.3 years) accepted to participate. Of these, 308 (85.5%) patients were receiving DMT at the time of the survey. Some 198 (63.7%) were receiving injectable therapies. Optimal adherence was 47.7%. Adherence was associated with oral medication [odds ratio (OR) 1.83 95% confidence interval (CI) 1.13–3.00, p = 0.014]. A factor related to oral drugs was higher educational level (OR 2.86 95%CI 1.41–5.81, p = 0.004).
Conclusion:
This real-world study showed better adherence and persistence on treatment with oral therapies in MS patients in Argentina.
dc.description.abstract
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: GZ disclosed receipt of the following financial support for the research, authorship and/or publication of this article: this study was supported by a research grant awarded by the Florencio Fiorini Foundation. The article processing charges was funded by Roche.
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
SAGE Publications
dc.relation
Therapeutic Advances in Neurological Disorders;14
dc.relation
https://doi.org/10.1177/17562864211031099
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Esclerosi múltiple - Tractament
dc.subject
Medicació oral
dc.subject
Pacients - Cooperació
dc.subject
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Attitude::Attitude to Health::Treatment Adherence and Compliance::Patient Acceptance of Health Care::Patient Compliance::Medication Adherence
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Drug Administration Routes::Administration, Oral
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::actitud::actitud ante la salud::cumplimiento y adherencia al tratamiento::aceptación de la asistencia sanitaria por parte del paciente::cumplimiento del paciente::adhesión a la medicación
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::vías de administración de medicamentos::administración oral
dc.title
Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
